Academic Journal
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
| العنوان: | Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study |
|---|---|
| المؤلفون: | Licitra, L., Tahara, M., Harrington, K., de Mendoza, M. Olivera Hurtado, Guo, Y., Aksoy, S., Fang, M., Żurawski, B., Csőszi, T., Klochikhin, M., de Oliveira, T.B., Takahashi, S., Yang, M.H., Swiecicki, P.L., O'Hara, K., Shen, J., Wang, A., Gumuscu, B., Benjamin, K., Haddad, R.I. |
| المصدر: | International Journal of Radiation Oncology*Biology*Physics ; volume 118, issue 5, page e2-e3 ; ISSN 0360-3016 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2024 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.ijrobp.2024.01.016 |
| الاتاحة: | http://dx.doi.org/10.1016/j.ijrobp.2024.01.016 https://api.elsevier.com/content/article/PII:S0360301624000609?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0360301624000609?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ |
| رقم الانضمام: | edsbas.F285E961 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ijrobp.2024.01.016 |
|---|